- Home
- BIIB
BIIB
Biogen Inc.
as 07-26-2024 4:00pm EST
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
Upcoming Earnings Alert:
Get ready for potential market movements as Biogen Inc. BIIB prepares to release earnings report on 01 Aug 2024.
| Founded: | 1978 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 32.8B | IPO Year: | 1991 |
| Target Price: | $284.41 | AVG Volume (30 days): | 946.6K |
| Analyst Decision: | Buy | Number of Analysts: | 22 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 8.01 | EPS Growth: | -62.83 |
| 52 Week Low/High: | $189.44 - $278.95 | Next Earning Date: | 08-01-2024 |
| Revenue: | $9,663,100,000 | Revenue Growth: | -4.37% |
| Revenue Growth (this year): | -1.26% | Revenue Growth (next year): | 0.35% |
Stock Insider Trading Activity of Biogen Inc. (BIIB)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rowinsky Eric K | BIIB | Director | Feb 15 '24 | Buy | $222.54 | 455 | $101,255.70 | 20,629 | SEC Form 4 |
Latest Biogen Inc. News
BIIB Breaking Stock News: Dive into BIIB Ticker-Specific Updates for Smart Investing
Investor's Business Daily
5 hours ago
Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug
MT Newswires
9 hours ago
RBC Capital Adjusts Price Target on Biogen to $282 From $303
Barrons.com
10 hours ago
EU Rejection of Alzheimer’s Drug Is Another Disappointment for Biogen
Benzinga
10 hours ago
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
MT Newswires
11 hours ago
Baird Adjusts Price Target on Biogen to $294 From $316
Zacks
11 hours ago
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
Associated Press Finance
11 hours ago
European committee says Alzheimer's treatment Leqembi shouldn't get marketing approval
MT Newswires
13 hours ago
Biogen Shares Drop After EMA Panel's Negative Opinion on Alzheimer's Disease Drug
Compare BIIB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BIIB Biogen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.